Venkateswara Rao et.al Indian Journal of Research in Pharmacy and Biotechnology ISSN: (Print) ISSN: (Online)

Transcription

1 Design and development of Metformin hydrochloride Tried sustained release tablets Venkateswara Rao T 1 *, Bhadramma N 1, Raghukiran CVS 2 and Madubabu K 3 Bapatla College of Pharmacy, Bapatla, Guntur Tigala Krishna Reddy College of Pharmacy, Hyderabad. Hetro Drugs Ltd, Hyderabad Corresponding author: tv_rao2@yahoo.com ABSTRACT Diabetes is one of the major causes of death and disability in the world. Diabetes results from decreased secretion of insulin, decreased insulin action or both. The main aims of the investigation was to design and development of tri floating tablets of metformin hydrochloride and also study the influence of concentrations of HPMCK 100 on various properties of tablet and tri- tablets were formulated by wet granulation method. Drug - excipient compatibility studies were conducted by FTIR spectroscopy. The prepared granules, tablets were evaluated. In-vitro release data revealed that F5 formulation sustained the release for 12 hours and the release data was fitted into zero order, first order, Higuchi and Peppas equations. The drug release from the formulation followed zero kinetics and exhibits Peppas mechanism. Release exponents n was found less than 0.85 indicating the release governed by non-fickian anomalous transport mechanism. Key words: Tri i floating tablets, Hydroxy propyl methyl cellulose (HPMCK100) INTRODUCTION Diabetes is one of the major causes of death and disability in the world. Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia (fasting plasma glucose 7.0 mmol / 1 or 2 hours post 75 g oral glucose load plasma glucose 11.1 mmol / on two or more occasions). Diabetes results from deficient insulin secretion, decreased insulin action, or both. The oral route of drug administration was most convenient method for controlled delivery of drug. It provides the continuous oral delivery of a drug also the system that target the delivery of a drug to a specific region within the GI tract for either local / systemic action. One of the most feasible approaches for affecting a prolonged and predictable drug delivery in the GI tract is to control the GRT. Metformin hydrochloride is an antihyperglycemic agent, which improves the glucose tolerance in type 2 diabetes. People with type 2 diabetes are not able to make enough insulin or respond normally to the insulin their bodies make. This leads to serious medical problems including kidney damage, amputations and blindness. The absolute bioavailability of Metformin hydrochloride is 50-60%, biological half life is hours and the main site of absorption of metformin hydrochloride is proximal end of small intestine. The HBS system was planned for Metformin hydrochloride as such a system when administered it remain buoyant on the gastric fluids for a prolonged period of time and the drug it remain buoyant on the gastric fluids for a prolonged period of time and the drug would be available in the dissolved format. This would leads to improvement in the bioavailability of the drug, to increase its bioavailability gastro retentive drug delivery systems were choosen for development in the form of tablet. In this way it stands as an advantage over conventional dosage form, which needs to be administered twice or thrice a day. MATERIALS AND METHODS Metformin hydrochloride was received from Alkem laboratories ltd, Mumbai as gift sample, HPMC, sodium bicarbonate, talc was procured from S.D fine chem.all other chemicals and solvents used in this study were LR grade Preparation of tri-i Metformin Hydrochloride floating tablets: The preparation of tri tablet involves three steps and the granules were prepared by wet granulation method using water as binding solution, lactose as diluent. Formulation of the upper and bottom : The granules for upper and bottom were prepared as per the formulae shown in table no 1.1.The cohesive mass were prepared passed through sieve no 12. The granules were dried in an oven at 55 0 for 2 hrs. the dried granules were passed through sieve no 16, lubricated with talc and magnesium stearate for compression into tablet. Formulation of the middle : The granules were prepared by wet granulation method as per the formulae shown in table no 1.1.The dough mass was prepared by the addition of water as binding a solution into the mixture of drug, polymer and diluent. The obtained dough mass was passed through sieve no 12, granules were dried in an oven at 55 0 for 2hrs. The dried granules were passed through sieve no 16. The IJRPB 1(6) November December 2013 Page 893

2 upper bottom upper bottom upper bottom upper bottom upper bottom dried granules were mixed with talc and magnesium stearate, then subjected to compression. Compression of tri tablet: The compression of the tablet involves three steps. The granules for bottom were compressed slightly, then the granules for middle were poured over the above compact, again compressed with minimum force to form a second and then top granules were added over the above, then compressed into a tablet by Cadmach Rotary tablet machine ie tried tablet by using a16 mm flat - faced punches. Table.1.Composition of metformin hydrochloride tri floating tablets with HPMC K100M Ingredients ( mg/ tablet) F1 F2 F3 F4 F5 Metformin hydrochloride HPMC K 100 M Sodium bicarbonate Lactose Talc Magnesium stearate Total weight Characterization of granules: The prepared granules were evaluated for the following parameters[10,11]. Bulk density: The bulk density was determined by measuring the volume occupied by the pre weighed granules,it was calculated by the following equation. Bulk density = Mass of Granules /Volume of packing Tapped bulk density: The granules whose weight was determined earlier was transferred in to 100ml of graduated cylinder and subjected to 100 taps. Then the volume occupied by the granules (Tapped volume) were determined. Tapped density was calculated by the following formula Tapped density = Mass of granules/tapped volume Carr'sindex: The percentage of compressibility of granules was determined by Carr's/Compressibility index. Carr's index (%) = Tapped density- Bulk density /tapped density 100 Hausner s ratio: Hausner ratio of granules determined by comparing the tapped density to the bulk density by using the formulae Hausner,s ratio = Tapped density/bulk density Angle of repose: The prepared granules were assessed for its flow property by determining the angle of repose by open tube method. The angle of repose was determined by the following formula h = height of heap r = radius of the base. Loss on drying: Granules (Igm) were kept in an oven at 105 c and dried up to constant weight. Loss on drying was calculated using the following formulae. Loss on drying = (Initial weight - Final weight)/initial weight 100 Moisture content: Granules (1gm) were kept in an oven at 105 c and dried up to constant weight. Moisture content was calculated using the following formulae. Moisture content = (Initial weight - Final weight)/final weight 100 Evaluation of tablets: The formulated tablets were evaluated for the following parameters. Thickness: The thickness and diameter of the formulated tablets were measured by using Vernier calipers. IJRPB 1(6) November December 2013 Page 894

3 Weight variation: The formulated tablets were tested for weight uniformity. 20 tablets were collectively and individually. From the collective weight, average weight was calculated. Each tablet weight was then compared with average weight to ascertain whether it is within permissible limits or not. % Weight Variation = (Average weight-individual weight)/ average weight 100 Hardness: The tablet crushing strength, which is the force required to break the tablet by compression in the diametric direction was measured in triplicate by using Pfizer tablet hardness tester. Friability: The Roche friability test apparatus was used to determine the friability of the tablets. 20 pre weighed tablets were placed in the apparatus, which was subjected to 100 revolutions. Then the tablets were reweighed. The percentage friability calculated was using the formula. % Friability = Initial weight- Final weight / initial weight 100 characteristics: characteristics were determined by using USP dissolution XI apparatus at 100 rpm using 900 ml of 0.1 N HCl and temperature was maintained at 37 c. lag time: The tablet was placed in dissolution apparatus and the time taken to float on the dissolution medium was noted. time: The total duration of the time that the tablets float on dissolution medium was noted. Swelling index: Tablet was weighed (W 0 ) and placed in dissolution medium containing 0.1N HClmaintained at 37 c. At predetermined time intervals the tablet was and blotted to remove excess water and weighed (Wt). The percentage of swelling index calculated. Swelling index = (W t - W o )/W t x 100 W t = final weight of the tablet W o = initial weight of the table Drug content: Twenty tablets were weighed and powdered. The quantity of powder equivalent to 100 mg of Metformin hydrochloride was dissolved in 0.1 N HC1 diluted to 100ml with 0.1N HC1 then the solution was filtered and suitably diluted. The drug content was estimated spectrometrically at 233 nm. In-vitro dissolution studies: In-Vitro dissolution studies were conducted by using USP type II paddle dissolution apparatus with 900ml of 0.1N Hydrochloric acid as dissolution medium, maintained the temperature of medium at 37±0.5 and stirrer speed at 100 rpm. 5 ml of aliquots of dissolution medium was withdrawn at regular time intervals and the same volume of pre-warmed (37±0.5 ) fresh dissolution medium was replaced. The samples were filtered and drug content of Metformin hydrochloride in each sample was analyzed after suitable dilutions, filtered and filtrates are analyzed by Shimadzu UVspectrophotometer at 233 nm. RESULTS AND DISCUSSION Drug- excipient compatibility studies were conducted by FTIR spectroscopy, results revealed that no chemical interactions were observed from the FTIR as shown in fig 2, 3 and 4. The prepared granules for floating and sustained release were evaluated found to have free flow properties, results given in table 2 and also the tablets were subjected to thickness, weight variation, hardness, floating time, floating log time, swelling index, drug content and in-vitro dissolution studies.the thickness of the tablets was found in the range of mm to mm. The weight variation ranged between to , the hardness of the floating tablets were ranged between 6.0 kg/cm 2 to 7..3kgcm 2. The percent friability of prepared tablets was well as within the acceptable limit. The range between the formulations had desired floating log time to mg and total floating time found between 6.5-9hrs regardless of concentrations of polymers incorporated, results given in the table 3. The swelling index result was observed in a range between ± 0.02 to ± 0.03, that increase in percent swelling was increasing with increasing concentration of polymers. The drug content in all formulations was within the range of 499.2mg ± 0.01 to 499.5mg ± 0.03, ensuring the uniformity of the drug content in the formulation. The percentage of drug release for F1, F2, F3, F4, F5 were found to be ± 0.23, ± 0.53, ± 0.04, ± 0.85 and ± at the end of 6.5, 7.5, 8.5, 9 and 11hours respectively, in vitro release profiles as shown in fig 1. In vitro release data fitted into the zero order, first order, matrix and peppas equations. The formulations followed zero order kinetics and exhibited peppas transport mechanism, release exponent found less than 1, indicates non fickian diffusion mechanism. Results revealed that as concentration of polymer increases, the floating time was found to be increased and prolonged the release of the drug due to the swelling of HPMC and high uptake of medium, floating time influenced by the gas generating agent and also it influences the drug release. Among all prepared formulation F5 sustained the release for prolonged time; hence it was suitable for the sustained release for the patient in the treatment of diabetes and enhances the bioavilabilty of the drug in the form of floating delivery system. In tri tablet, the drug was sustained for prolonged period of time due to the gelling property of polymer and drug sand witched between the two s formulated with the HPMCK100M so drug release was prolonged for more time. IJRPB 1(6) November December 2013 Page 895

4 % Drug Released Table.2.Characterization of Metformin hydrochloride trilateral floating granules formulated with HPMC K100M Formulations Bulk density(g/ml) Tapped density(g/ml) Carr s index (%) Hausner s ratio Angle of repose ( 0 ) Loss on drying (%) Moisture content (%) F ± ± ± ± ± ± ±0.01 F ± ± ± ± ± ± ±0.03 F ± ± ± ± ± ± ±0.02 F ± ± ± ± ± ± ±0.04 F ± ± ± ± ± ± ±0.01 Table.3.Characterization of Metformin hydrochloride tri floating tablets formulated with HPMC K 100 M Formulations Thickness(mm) Weight variation(%) Hard ness(kg/cm 2 ) Friability( %) lag time(min) Floting time (hr) Swelling index)(%) Drug content(mg) F1 3.1± ± ± ±0.01 4± ± ±0.01 F2 3.5± ± ± ±0.02 4± ± ±0.03 F3 3.5± ± ± ±0.03 4± ± ±0.01 F4 3.8± ± ± ±0.02 3± ± ±0.05 F5 3.8± ± ± ±0.04 3± ± ±0.03 Figure.1. Dissolution profiles of Metformin hydrochloride bi floating tablets formulated with HPMC k100m F1 F2 F3 F4 F Time(hrs) Figure.2.IR spectrum of Metformin hydrochloride Figure.3. IR Spectrum of HPMC K 100 M IJRPB 1(6) November December 2013 Page 896

5 Figure.4. IR spectrum of best formulation CONCLUSION The objective of present study was design and development of tri-ed floating tablet of Metformin hydrochloride for sustained the release. The HPMCK 100M as a polymer more reliable and sustained the drug for a prolonged period of time by increasing the concentration of it. More over the high swelling property of the polymer helped in maintaining the buoyancy with the minimal utilization of gas evolving excipients such as sodium bicarbonate which increased a marked impact on the gastro intestinal fluids by its alkaline nature. The formulations followed zero order kinetics and exhibits the peppas transport mechanism and hence finally concluded that tri formulations were found to be suitable for the floating drug delivery systems. REFERENCES Atyabi F, Sharma HL, Mohammed HAH, Fell JT, In vivo evaluation of a novel gastro retentive formulation based on ion exchange resins, J. Control Release, 42, 1996, Dave B.S, Amin A.F & Patel M.M, G astro retentive drug delivery system of ranidine hydrochloride formulation and in vitro evaluation, AAPS Pharm. Sci. Tech, 5(2), 2004, 1-6. Hwang J, H. Park, K. Park, Gastric retentive drug delivery systems, Drug carrier Syst, 15, 1998, Indian pharmacopoeia, The controller of publications, New Delhi, 4 th edition, vol II, 1996, 469. Vantrappen GR., Peeters TL, Janssen SJ, The secretary component of interdigestive migratory motor complex in man: scan d J. Gastro enterol, 19, 1979, Yeole P.G, Khan S., Patel V.F, drug delivery systems: Need and development, Indian. J. pharma.sci, 67(3), 2005, IJRPB 1(6) November December 2013 Page 897